Diagnostic Imaging for Memory Loss
Start with MRI head without IV contrast as the initial imaging modality for all older adults presenting with new-onset memory loss 1, 2.
Initial Imaging Approach
MRI head without IV contrast is the most appropriate first-line imaging study because it:
- Identifies treatable structural causes that mimic cognitive impairment (subdural hematomas, intracranial masses, normal pressure hydrocephalus) 1
- Detects hippocampal atrophy, which predicts conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) 1
- Reveals cerebrovascular disease patterns that contribute to mixed dementia pathology 3
- Provides superior anatomic detail compared to CT for assessing cortical atrophy patterns and white matter changes 1
The 2025 ACR Appropriateness Criteria explicitly recommend MRI as the primary structural imaging modality, with CT reserved only when MRI is contraindicated or unavailable 1.
When to Add Advanced Imaging
Amyloid PET/CT is appropriate when:
- Age <65 years with suspected AD 1
- Atypical presentations that don't fit classic AD patterns 1
- Diagnostic uncertainty after initial workup with MRI 1
- Before initiating anti-amyloid monoclonal antibody therapy (required for treatment eligibility) 1
- CSF biomarkers are equivocal or inconclusive 1
Amyloid PET changes diagnosis in 25-44% of cases and increases diagnostic confidence 1. However, it is rarely appropriate when CSF biomarkers are already conclusive 1.
FDG-PET/CT adds value when:
- Distinguishing between dementia subtypes (AD shows temporal-parietal hypometabolism; frontotemporal dementia shows frontal hypometabolism; dementia with Lewy bodies shows parieto-occipital involvement) 1
- Predicting MCI conversion to dementia (negative FDG-PET makes progression unlikely) 1
- Combined with amyloid PET for improved diagnostic accuracy 1
FDG-PET has 95% sensitivity and 73% specificity for differentiating AD from non-AD dementias 1.
What NOT to Order
Avoid CT with IV contrast or CT without and with IV contrast - there is no evidence supporting their use in routine dementia evaluation 1.
CT without contrast is acceptable only when MRI is contraindicated, but it has inferior sensitivity for detecting hippocampal atrophy and early neurodegenerative changes 1.
Common Pitfalls
- Ordering CT instead of MRI routinely: CT misses subtle hippocampal atrophy and early cortical changes that MRI detects 1
- Ordering amyloid PET too early: Get structural imaging and basic workup first; amyloid PET is for specific clinical scenarios, not screening 1
- Ignoring cerebrovascular disease: Mixed pathology is common in older adults; MRI identifies vascular contributions that affect prognosis and treatment 3
- Assuming normal imaging rules out dementia: Neuroimaging is supportive, not diagnostic; clinical evaluation and neuropsychological testing remain essential 4, 5
Clinical Context
The imaging strategy should be guided by:
- Clinical presentation: Typical amnestic presentation versus atypical features (language, visuospatial, behavioral changes)
- Age of onset: Earlier onset (<65 years) warrants more aggressive workup including amyloid PET 1
- Rate of progression: Rapidly progressive dementia requires broader differential and may need additional imaging 6
- Treatment implications: If anti-amyloid therapy is being considered, amyloid PET becomes necessary 1
The goal is identifying treatable causes first, then characterizing neurodegenerative patterns to guide prognosis and emerging disease-modifying therapies 1, 2.